AXQ Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

AXQ Capital LP bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 18,126 shares of the biopharmaceutical company’s stock, valued at approximately $171,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Sciencast Management LP purchased a new stake in Amicus Therapeutics during the fourth quarter valued at about $100,000. Semanteon Capital Management LP increased its position in shares of Amicus Therapeutics by 40.9% during the 4th quarter. Semanteon Capital Management LP now owns 149,156 shares of the biopharmaceutical company’s stock valued at $1,405,000 after purchasing an additional 43,288 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in shares of Amicus Therapeutics by 18.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,927 shares of the biopharmaceutical company’s stock valued at $621,000 after buying an additional 10,218 shares in the last quarter. Xponance Inc. lifted its position in Amicus Therapeutics by 11.9% in the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 2,249 shares during the last quarter. Finally, Intech Investment Management LLC boosted its stake in Amicus Therapeutics by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock worth $1,175,000 after buying an additional 46,633 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $8.69 on Tuesday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of -48.28, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a one year low of $8.55 and a one year high of $12.65. The company’s 50-day moving average is $9.34 and its 200 day moving average is $10.04.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.